MarketCap
BioCryst Pharmaceuticals BCRX
$ 7.69
2.4%
Facebook
X
Telegram
BioCryst Pharmaceuticals ROE Ratio | BCRX
Annual ROE Ratio BioCryst Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -221.45 | 18.68 | 49.73 | 83.88 | 172.04 | 949.09 | -284.68 | -205.65 | -78.53 | -3494.55 | -90.14 | -59.75 | 2673.89 | 8608.15 | -384.63 | -51.68 | -15.59 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8608.15 | -3494.55 | 451.11 |
Quarterly ROE Ratio BioCryst Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -102.8 | -96.58 | -80.53 | -210.87 | 1.09 | 7.41 | 11.28 | 18.72 | 26.64 | 32.44 | 49.16 | 57.97 | 68.7 | 77.43 | 85.66 | 114.59 | 106.93 | 129.39 | 142.51 | 183.06 | 480.49 | 303.41 | 463.11 | 572.59 | 251.68 | 479.9 | 688.79 | 355.62 | 306.76 | 155.52 | -291.27 | -205.65 | -173.26 | -128.19 | -110.88 | -75.5 | -337.53 | -1053.04 | -2064.63 | -3494.55 | -3247.19 | -2547.28 | -1505.26 | -90.14 | -67.57 | -48.48 | -78.12 | -59.75 | 437.84 | 1159.95 | 2260.31 | 2673.89 | 4626.32 | 6052.32 | 7675.29 | 8608.15 | 6084.47 | 3850.25 | 1036.39 | -384.63 | -97.66 | -109.89 | -87.98 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8608.15 | -3494.55 | 522.01 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Daré Bioscience
DARE
|
-471.39 | $ 0.64 | 2.96 % | $ 7.15 M |  USA |
 |
Fate Therapeutics
FATE
|
-65.79 | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-5480.55 | $ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
649.18 | $ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
36.91 | $ 15.16 | 6.76 % | $ 13 B |  China |
 |
Aptorum Group Limited
APM
|
-5.9 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-38.55 | $ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
-146.12 | $ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
66.92 | $ 0.05 | -14.81 % | $ 547 | USA |
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
BioAtla
BCAB
|
164.71 | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
22.46 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
145.53 | $ 24.77 | -3.73 % | $ 1.19 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
9.32 | $ 13.47 | 4.1 % | $ 1.2 B | USA |
 |
ARCA biopharma
ABIO
|
-22.34 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-12.2 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-768.34 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-29503.56 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-75.78 | $ 0.36 | 0.59 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
-6424.68 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-86.94 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
22.71 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-111.65 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
43.82 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43.82 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-148.0 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
49.5 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
39.47 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
7.51 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-0.53 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-110.36 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-610.73 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
70.93 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
-9.89 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-227.96 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-87.29 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
0.08 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
445.14 | - | -11.23 % | $ 9.65 M | USA |